Synnovation Therapeutics is focused on developing precision medicine through the creation of small molecule therapies that target validated disease mechanisms, particularly in cancer treatment. The company emphasizes the importance of achieving best-in-class pharmacology, which involves optimizing the potency and selectivity of their therapeutic agents. By leveraging their expertise in cancer biology and a skilled medicinal chemistry team, Synnovation is building a diverse pipeline of novel targeted therapies aimed at improving patient outcomes and transforming cancer care through a patient-centered approach.

The company's pipeline includes several promising candidates, such as SNV1521, which targets the selective PARP1 enzyme, and SNV4818, designed to be a mutant-selective inhibitor of the PI3Kα pathway. These compounds are part of a broader strategy to address significant unmet medical needs in oncology by enhancing the pharmaceutical properties of existing treatments. Synnovation's commitment to advancing these agents into clinical trials reflects their goal of providing innovative solutions that can overcome the limitations of current standards of care and significantly improve the lives of patients battling cancer.

United States

Synnovation Therapeutics is a precision medicine company developing small molecule therapies optimized to achieve best-in-class pharmacology against highly validated disease targets.

We are dedicated to the discovery and development of best-in-class therapeutics that can improve the lives of people living with cancer. Leveraging deep expertise in cancer biology and a world class medicinal chemistry team, we are building a diverse pipeline of novel small molecule targeted therapies. Our mission is to efficiently advance these agents into clinical trials with the goal of transforming cancer care through patient-focused precision medicine.

Synnovation Therapeutics

Company Details